Please assess the completion status of the following clinical trial:

Trial Title: Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of multiple myeloma~  * Newly diagnosed disease~ * Durie-Salmon stage II or III disease~* Measurable disease, defined by any of the following:~  * Measurable serum and/or urine M-protein levels documented and available prior to induction therapy~ * Positive serum free light chain assay~* Must have completed a minimum of 3 courses of myeloma specific therapy~* Candidate for autologous stem cell transplantation~* Patients who have achieved a complete remission at the time of bone marrow harvest for marrow infiltrating lymphocytes (MILs) expansion are not eligible~* No evidence of spinal cord compression~* Diagnosis of the following cancers are not allowed:~  * POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes)~ * Non-secretory myeloma (no measurable protein on serum free light chain assay)~ * Plasma cell leukemia~* No amyloidosis~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Life expectancy ≥ 6 months~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and up to day 180~* Corrected serum calcium \< 11 mg/dL and no evidence of symptomatic hypercalcemia~* Total bilirubin ≤ 2.0 times upper limit of normal (ULN)~* ALT ≤ 2.0 times ULN~* Serum creatinine \< 2.0 mg/dL~* No history of other malignancy within the past 5 years, except adequately treated basal cell or squamous cell skin cancer~* No history of autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus) requiring systemic treatment~  * Hypothyroidism without evidence of Graves' disease or Hashimoto thyroiditis is allowed~* No infection requiring treatment with antibiotics, antifungal, or antiviral agents within the past 7 days~* No HIV infection~* No major organ system dysfunction including, but not limited to, the following:~  * New York Heart Association class III or IV congestive heart failure~ * Pulmonary disease requiring the use of inhaled steroids or bronchodilators~ * Renal, hepatic, gastrointestinal, neurologic, or psychiatric dysfunction that would impair ability to participate in the study~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior hematopoietic stem cell transplantation~* At least 3 weeks since prior corticosteroids (i.e., glucocorticoids)~* At least 3 weeks since prior myeloma-specific therapy~* At least 4 weeks since participation in any clinical trial that involved an investigational drug or device~* No concurrent therapy with any of the following:~  * Corticosteroids (e.g., hydrocortisone, prednisone, prednisolone, dexamethasone \[Decadron\])~    * Inhaled steroids used for treatment of allergic rhinitis or pulmonary disease allowed~ * Thalidomide~ * Interferon~ * Growth factors, interleukins, or other cytokines (except filgrastim \[G-CSF\] as outlined in the protocol, or erythropoietin)~ * Cytotoxic chemotherapy agents (except cyclophosphamide for stem cell mobilization and high-dose melphalan)~ * Immunosuppressive drugs~ * Experimental therapies~ * Radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASCT+MILs (Type: EXPERIMENTAL): Autologous stem cell transplant with a conditioning regimen of melphalan 100 mg/m\^2 on each of Days -2 and -1. Infusion of activated marrow infiltrating lymphocytes (MILs) on Day 3. PCV13 vaccine will be given before and/or after Day 0 depending on when participants are enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).